Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $7.3 million.

  • Nurix Therapeutics' Other Non-Current Assets rose 13238.37% to $7.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $7.3 million, marking a year-over-year increase of 13238.37%. This contributed to the annual value of $7.3 million for FY2025, which is 13238.37% up from last year.
  • Nurix Therapeutics' Other Non-Current Assets amounted to $7.3 million in Q4 2025, which was up 13238.37% from $7.4 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Other Non-Current Assets high stood at $7.4 million for Q3 2025, and its period low was $901000.0 during Q1 2022.
  • Its 5-year average for Other Non-Current Assets is $2.5 million, with a median of $901000.0 in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Other Non-Current Assets skyrocketed by 168054.05% in 2021 and then plummeted by 7264.72% in 2022.
  • Over the past 5 years, Nurix Therapeutics' Other Non-Current Assets (Quarter) stood at $2.8 million in 2021, then tumbled by 68.2% to $901000.0 in 2022, then changed by 0.0% to $901000.0 in 2023, then soared by 250.61% to $3.2 million in 2024, then skyrocketed by 132.38% to $7.3 million in 2025.
  • Its Other Non-Current Assets was $7.3 million in Q4 2025, compared to $7.4 million in Q3 2025 and $6.3 million in Q2 2025.